Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Results Preview: Can BMS pull itself up from the trough?

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb's share price dropped by 7.5% to $32.59 between the end of 2011 and 31 December 2012. Not a great year for the US drug maker? Well, most of the stock price negativity was associated with two related events: the $2.5 billion acquisition of Inhibitex announced in January, and the subsequent failure in August of the lead program from that acquisition (the Phase II nucleotide polymerase inhibitor BMS-094 for hepatitis C;, 24 August 2012). This setback was not helped by BMS's failure to convince its rival Gilead to collaborate in hepatitis C.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts